Comment by Simon Goldman, investment director, UCL Technology Fund

Biomedical platform technologies are appealing because they can create impact (and therefore revenues) in multiple markets or indications, with less investment needed to get there. The commonalities between products arising from a platform, such as a shared manufacturing process, result in scalability. Venture capitalists adore this because it increases the chances of realising a much bigger return for a given investment – the same process produces multiple revenue streams. But they are only going to value the platform in all…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?